International journal of cancer
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission.
Brian H Kushner, Charlie White, Audrey Mauguen, Fiorella Iglesias Cardenas, Ellen M Basu, Wei Wei, Kim Kramer, Shakeel Modak
Published: 202610.1002/ijc.70329
Abstract
Naxitamab + GM-CSF was effective against chemo-resistant high-risk neuroblastoma (HR-NB), leading to approval by the Food and Drug Administration. We now describe toxicity and outcome of patients treated in first complete remission (CR) with naxitama…
Preview only. Read the full abstract at the source